Introduction
THE LIVER PLAYS A CENTRAL ROLE in the maintenance of sterol balance across the whole body because not only is it the organ that receives most of the cholesterol absorbed by the small intestine, but also it is the site for the degradation and excretion of cholesterol through the bile (40). The liver also actively synthesizes cholesterol but the rate at which it does so varies widely depending on numerous factors and, in particular, the amount of cholesterol being delivered to it from the small intestine (40). It is well documented that dietary or pharmacologic manipulation of the enterohepatic flux of either cholesterol or bile acids can potentially cause marked changes in the rate at which the liver synthesizes cholesterol, converts cholesterol to bile acids, incorporates cholesterol into very low-density lipoproteins (VLDL), esterifies and stores cholesterol, or secretes unesterified cholesterol directly into bile (18, 22, 40) . Such changes in the intrahepatic handling of cholesterol can, in turn, lead to clinically significant shifts in the circulating low density lipoprotein-cholesterol (LDL-C) concentration and in the degree of biliary cholesterol saturation (15, 43, 48) .
The intestinal absorption of cholesterol has long been a key target in the management of dyslipidemia primarily because of the substantial quantity of cholesterol that reaches the liver daily from the small bowel (5, 35) . In the average adult consuming a typical Western diet ~1200 to 1700 mg of cholesterol enters the lumen of the small intestine each day (18) . Approximately 300 to 500 mg of this cholesterol comes from the diet and the remainder is derived largely from bile (19) . Given that in humans fractional cholesterol absorption averages around 50 %, the amount of intestinally derived cholesterol delivered to the liver throughout the day amounts to hundreds of milligrams (8, 34 ). This occurs through what is essentially a triphasic process that begins with a series of events within the lumen which culminate in the micellar solubilization of cholesterol and its movement up to the brush border membrane of the absorptive enterocyte (41).
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The second phase entails the transport of cholesterol, as well as non-cholesterol sterols, across this limiting membrane facilitated by Niemann Pick C1 Like1 (NPC1L1) (1, 13) . Within the enterocyte, cholesterol is esterified and subsequently incorporated, along with other lipids and apolipoprotein B48, into nascent chylomicrons. These latter processes together constitute the third phase of sterol absorption. Although the cellular and molecular events involved in each of these phases are generally well defined, there are nevertheless significant gaps in our knowledge of how cholesterol movement within the enterocyte is facilitated (49). Furthermore, while NPC1L1 clearly plays a fundamental role in sterol absorption, there is currently not unanimous agreement that it is this protein which facilitates the uptake of sterols across the brush border membrane (38).
While the primary focus of research on the molecular control of cholesterol absorption has been to find more effective ways of modifying the plasma lipoprotein composition to lessen an individual's risk of developing atherosclerosis, the question of how changes in chylomicron cholesterol uptake by the liver might also alter the rate of biliary cholesterol secretion, and thus a person's predisposition to cholesterol gallstone formation, has not been as widely investigated.
Most of the studies that have been carried out in animal models such as the baboon, squirrel monkey, Golden Syrian hamster, mouse, and prairie dog, as well as in humans, have shown that increases in dietary cholesterol intake result in a rise in biliary cholesterol content (2, 3, 14, 21, 24, 27, 28, 50, 52). However, the extent to which this happens varies markedly depending on the type of model and the dietary formulation that were utilized. Comparatively, much less is known about the converse situation involving the use of inhibitors that diminish the amount of cholesterol reaching the liver from the small bowel. Studies with agents that interfere with the intraluminal phase of absorption such as β-sitosterol, sucrose polyester (a nonabsorbable fat substitute), and surfomer (AOMA, a copolymer of maleic acid and an 18-carbon α-olefin), all REGULATION OF BILIARY CHOLESTEROL SECRETION IN HAMSTERS 5 showed either no change or a modest reduction in biliary cholesterol saturation (6, 10, 11) . The impact of agents that act at the intracellular phase of sterol absorption has not been widely studied. However, the focus of attention has now shifted to ezetimibe, an entirely new class of inhibitors that, in milligram doses, markedly reduces cholesterol absorption by inhibiting NPC1L1 activity in the brush border membrane (17) . The dose of ezetimibe needed to block cholesterol absorption varies between species because of wide differences in the affinity with which ezetimibe binds to NPC1L1 (20). In the LDL-receptor knockout mouse fed a lipid rich diet, the degree of increase in biliary cholesterol content was blunted substantially by the addition of ezetimibe to the diet (29). Similar findings have been recently reported for mice harboring constitutive hepatic LXR activity, and for gallstone-susceptible C57L mice fed a lithogenic diet (45). Ezetimibe has also been found to have beneficial effects in a murine model of cholecystosteatosis (26). There are also now newly published data showing that ezetimibe treatment lowered the degree of biliary cholesterol saturation in small groups of gallstone patients and overweight subjects without gallstones (51).
In the present studies the Golden Syrian hamster has been utilized as an alternate model to determine the impact of ezetimibe treatment on biliary lipid composition during periods of low and high dietary cholesterol intake, and to delineate the concomitant biochemical and molecular changes in sterol metabolism within the small intestine and liver. Previous studies have established that this small animal has features of cholesterol metabolism that more closely resemble those seen in the human and non-human primate than do species like the mouse and rat (44) . Utilizing this hamster model, the data demonstrate that ezetimibe, by blocking the transport of excess chylomicron cholesterol to the liver, was highly effective in preventing an otherwise pathologic increase in hepatic cholesterol storage and biliary cholesterol content. The data also show for the first time that the ezetimibe-induced changes in the expression of multiple genes 
MATERIALS AND METHODS

Animals and diets. Female and male Golden Syrian hamsters (mesocricetus auratus)
were obtained from either Charles River Laboratories, Wilmington, MA, or, for one experiment, from Harlan Sprague Dawley, Inc., Indianapolis, IN, in the weight range of 100 to 110 g. They were housed individually in plastic cages containing wood shavings and maintained in a room with alternating 12-h periods of light and darkness. The hamsters were adapted to these conditions for 2 weeks during which time they were fed a pelleted form of a cereal-based rodent diet (Wayne Lab Blox No. 8604; Harlan Teklad, Madison, WI). This was defined as the basal diet. It had cholesterol content of 0.02% (w/w) and a total lipid content of 4% to 5% (w/w). In some studies the meal form of the basal diet was enriched with cholesterol (1.0 % w/w) and safflower oil (10% w/w). In the initial ezetimibe dose response experiments, the hamsters were fed the basal diet containing only ezetimibe at levels that provided approximate doses of 0, 0.5, 1.0, and 2.0 mg/day per kg body weight (based on the consumption of 73 g of diet/day per kg bw) (44). In the studies with the lipid rich diet, the ezetimibe was provided in the diet at a single dose of 1.0 mg/day per kg bw. This dose was shown by other investigators to normalize combined dyslipidemia in obese, hyperinsulinemic male hamsters (47). Depending partly on the objective of the study, the hamsters were fed their respective experimental diet ad libitum for either 10, 21 or 34 days. All animals were studied in the fed state towards the end of the dark phase of their light cycle. All studies were approved by the Institutional Animal Care and Use Committee of The University of Texas Southwestern Medical Center.
Intestinal cholesterol absorption, fecal bile acid and neutral sterol excretion, and biliary lipid composition. The details of the methods used for measuring these parameters are described previously (32). Intestinal cholesterol absorption was determined as a fractional value (percentage) using a fecal dual-isotope ratio method (32). For tissue, plasma, and bile REGULATION OF BILIARY CHOLESTEROL SECRETION IN HAMSTERS 8 harvesting, the hamsters were anesthetized and exsanguinated from the abdominal aorta. The liver was exposed and the gallbladder accessed. Bile was taken from the gallbladder using a 1 ml plastic syringe fitted with a 25 gauge, 5/8 inch needle. The bile was then transferred to a microfuge tube after which aliquots were diluted in methanol for lipid composition analysis. The molar ratio of cholesterol in gallbladder bile was expressed as a percentage value. The rate of fecal bile acid excretion was taken as a measure of the rate of bile acid synthesis (44). Primers for each gene were obtained from the literature (16) or were designed using PrimerExpress software (PerkinElmer Life and Analytical Sciences Inc., Boston, MA) and validated by analysis of template titration and dissociation curves (46) (see Table 1 5'-CCCAGGACGAAGCAGAAGA. These cloning primers were designed according to regions of highest sequence similarity between the human (NM_003578), mouse (NM_146064) and rat (NM_153728) ACAT2 genes. The resulting 871-base pair product was sequenced and found to share 89% nucleotide identity with the mouse ACAT2 mRNA (NM_146064), and this novel sequence was subjected to the Primer Express algorithm to identify qPCR primers for measuring hamster ACAT2 mRNA levels. Statistical analysis of data. All data are reported as means ± SE for the specified number of individual animals. Differences between mean values were tested for statistical significance (P <0 .05) by an unpaired, two-tailed Student's t-test. All statistical analyses were performed using GraphPad Prism software (GraphPad Software, Inc., San Diego, CA).
RESULTS
Accelerated fecal loss of neutral but not acidic sterols accompanies ezetimibe-induced
block of cholesterol absorption. The data in Fig 
Expression of mRNA for NPC1L1 is highly localized in the small intestine in hamsters.
The data in in the small intestine far exceeded that seen in the other regions of the gastrointestinal tract, the liver and gallbladder, and various other extra-hepatic organs. The abundance of NPC1L1 mRNA in the gallbladder was greater than it was in the liver, but still < 1% of the level expressed in the small intestine.
Response of the small intestine to acute withdrawal of ezetimibe treatment. The main objective of this experiment was to determine how the small intestine responded when ezetimibe treatment was suddenly discontinued. In evaluating the data shown in Fig. 3 , it should be emphasized that in the case of the group of hamsters subjected to treatment withdrawal, they had already been off ezetimibe for 3 days at the time they, and the other groups of hamsters, were dosed with labeled sterols for the measurement of fractional cholesterol absorption. Hence, while the mRNA data for the hamsters taken off ezetimibe reflect measurements made 6 days after drug treatment had stopped, the fractional absorption data reflect what was happening in the small intestine over the fourth, fifth and sixth days following cessation of treatment. The data in treated hamsters was significantly different from that for the group given the basal diet alone (Fig. 4D) .
Diet induced cholesterol accumulation in liver and plasma was prevented by ezetimibe.
Western diets typically contain substantial amounts of triacylglycerol and cholesterol, particularly relative to endogenous synthesis rates. Thus, in order to examine the effect of this drug in a more relevant situation, female hamsters were fed for 28 days a diet containing 
Changes in hepatic relative mRNA levels for multiple proteins induced by lipid-rich diet
were attenuated by ezetimibe. The relative mRNA level for multiple proteins was determined in the livers of the hamsters used in the study described in the lipid-rich diet alone. These changes in message levels either did not occur or were far less pronounced in the hamsters given ezetimibe with the high fat, high cholesterol diet.
Diet-induced increase in biliary cholesterol content was prevented by ezetimibe. In the study with the female hamsters fed the lipid-rich diet (Figs. 5 and 6) the lipid composition of gallbladder bile was also determined (data not shown). The cholesterol, safflower oil-enriched diet caused only a modest rise in the molar ratio of cholesterol in the bile (1.4 ± 0.2% vs. 0.8 ± 0.2% in matching hamsters given the basal diet alone). In the group fed the lipid-rich diet with ezetimibe, the molar ratio of cholesterol was 0.9 ± 0.1%. However, it is known that the male of this species responds much more dramatically to dietary lipids (3). Consequently, these studies were repeated in male hamsters given the diets enriched with cholesterol and safflower oil. As shown by the data in Fig. 7A , this dietary formulation did raise the cholesterol concentration in the gallbladder bile 5.2-fold. There was also a 2.4-fold increase in the phospholipid concentration ( Fig. 7B ), but no change in the bile acid concentration (Fig. 7C) . Thus, while ezetimibe treatment alone did not change the molar ratio of cholesterol in the bile, the lipid-rich diet alone did increase this ratio 4.6-fold (Fig. 7D ). When this diet was given with ezetimibe, the increase in biliary cholesterol saturation was greatly diminished. Thus, increasing the flow of cholesterol into the liver of the male animal markedly increased the rate of secretion of sterol by the liver into bile and this effect was nearly completely obviated by the administration of ezetimibe.
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DISCUSSION
The discovery and development of the novel sterol absorption inhibitor, ezetimibe, has provided not only an effective new strategy for the management of primary hypercholesterolemia in the general population (5), but also a treatment for sitosterolemia, a rare disorder resulting from mutations in either ABCG5 or G8 that lead to the hyperabsorption of dietary sterols and premature atherosclerosis (30, 31). More recently, ezetimibe was found to be effective also in ameliorating liver dysfunction in a murine model of NPC disease, a multi-system disorder resulting from mutations in the NPC1 gene that encodes a protein involved in intracellular cholesterol transport (7) . Those studies showed that the sooner in life mice deficient in npc1 received daily treatment with ezetimibe, the better was the improvement in their plasma liver enzyme levels. This benefit correlated directly with the degree of reduction in hepatic cholesterol accumulation that resulted from the ezetimibe-induced inhibition of intestinal cholesterol absorption and the diminished delivery of chylomicron cholesterol to the liver. The efficacy of ezetimibe in treating liver dysfunction in humans with NPC disease has yet to be determined. The underlying objective of the present studies was to investigate whether ezetimibe might also be potentially useful in the prevention and treatment of yet another disorder of cholesterol metabolism, cholelithiasis. The premise for doing so stems from the results of studies performed in several animal models, including primates, and to some extent in humans, which together show that biliary cholesterol content is determined in part by the rate of hepatic chylomicron cholesterol clearance (2, 3, 14, 21, 24, 27, 28, 50, 52).
Two interrelated points regarding the design of the present studies warrant emphasis here.
One concerns the selection of the Golden Syrian hamster as the model for these experiments, while the other has to do with the types of dietary formulations to which ezetimibe was added.
Golden Syrian hamsters manifest significant gender differences in some aspects of cholesterol or less (3, 43) . This is also the case with the dog (4, 23) which was the first species in which biliary cholesterol content was measured following treatment with ezetimibe 1 . This comparison between the hamster and dog is emphasized here because of the finding that biliary cholesterol content increased in dogs given ezetimibe for one month. Despite this, treatment of dogs with ezetimibe at a very high dose (300 mg/day per kg bw) for one year did not result in gallstone formation or any other adverse hepatobiliary effects 1 . It should be noted that these findings were made in dogs maintained on a low cholesterol, low fat commercial canine diet (personal communication from Harry R. Davis at the Schering-Plough Institute). Thus, the second point to be made here concerns the type of diet that is used when cholesterol modifying agents like ezetimibe are being tested in animal models. Ideally, such studies should be conducted in animals given both their conventional regimens, as well as formulations that more closely mimic the diets typically consumed by humans. The Golden Syrian hamster was chosen as a model for the present studies, not only because it normally produces bile with a low degree of cholesterol saturation as dogs do but, moreover, because it is a species in which profound changes in biliary cholesterol saturation can be induced by specific dietary formulations (3, 43) . There are also a number of inherent similarities in several aspects of cholesterol metabolism between humans and the Golden Syrian hamster that made this species an appropriate model for these studies(44).
Four conclusions can be drawn from the initial set of experiments with hamsters given ezetimibe at different doses while being fed a basal, low-cholesterol, low-fat diet. The first is that, while there were dramatic increases in intestinal and hepatic sterol synthesis (Figs. 1D and   1E ), and fecal neutral sterol excretion (Fig. 1B) , there were no consistent changes in biliary lipid (Figs. 4A-4D ). There was a trend towards higher absolute cholesterol concentrations in the bile of the hamsters given ezetimibe, but this was not dose related ( Fig.   4A ). It should be emphasized that these effects of ezetimibe on sterol balance are not unique to this class of absorption inhibitor. For example, in hamsters given diets containing surfomer (alpha-olefin maleic acid), a polymeric non-absorbable agent that inhibits cholesterol absorption by making the surface environment of the brush border membranes of the enterocytes more hydrophilic, there is a marked stimulation of intestinal and hepatic sterol synthesis (39, 42), just as there is with ezetimibe. This is accompanied by a modest reduction in the relative cholesterol content of the bile (39), an effect also reported for a small number of human subjects given surfomer (11) . Taken together, these findings demonstrate that the marked compensatory increase in cholesterol synthesis in the liver that occurs when cholesterol absorption is inhibited does not drive biliary cholesterol secretion.
The second conclusion concerns the lack of change in plasma total cholesterol concentrations ( Fig. 1F ) under circumstances where there was a profound reduction in intestinal cholesterol absorption (Fig. 1A) and a markedly accelerated rate of fecal neutral sterol excretion (Fig. 1B) . Presumably, in the ezetimibe treated hamsters, the compensatory increase in intestinal and hepatic sterol synthesis (Figs. 1D and 1E ) fully balanced the additional loss of sterol from the body, so that there was no detectable impact on circulating plasma cholesterol levels in the face of a major reduction in cholesterol absorption. The lowest dose of ezetimibe given to the hamsters (0.5 mg/day/kg bw) corresponds to about four times the dose typically prescribed to humans (10 mg once daily). In subjects with a very low dietary cholesterol intake, this dose of ezetimibe reduced fractional cholesterol absorption by 58%, and increased fecal neutral sterol excretion by 81% (9) . There was also a 72% increase in whole body cholesterol synthesis.
Despite this, plasma LDL-cholesterol levels in these subjects fell, on average, by 17%. Thus, in these individuals, the compensatory increase in cholesterol synthesis, which presumably reflected increases mainly by the liver and small bowel, did not fully balance the increased loss of sterol from the body, thus leading to a fall in circulating LDL-cholesterol levels. Although no effect of ezetimibe on plasma cholesterol levels was seen in hamsters fed the basal diet, there was clearly a marked reduction when dietary cholesterol intake was raised (Fig. 5C ).
The third conclusion relates to the changes in the relative level of expression of mRNA for a number of key proteins involved in regulating sterol homeostasis in the enterocyte during, and following cessation of treatment with ezetimibe. It is particularly noteworthy that the relative mRNA level for NPC1L1 remained almost unchanged, irrespective of whether the hamsters were on or off ezetimibe treatment (Fig. 3B ). This was also true for the transcript level for ABCA1. In contrast, the mRNA level for ABCG5 and G8 fell significantly when ezetimibe was given, but returned to baseline values after withdrawal of treatment. Clearly, the reduced level of mRNA for ABCG5 and G8 reflected an ezetimibe induced deficit of cholesterol within the enterocyte, a condition that also triggered a marked induction of local cholesterol synthesis as evidenced not only by the increased mRNA levels for HMG CoA synthase and HMG CoA reductase, but also by direct measurements of the rate of small bowel sterol synthesis in vivo (Fig. 1D, 1G ). While these data clearly attest the impact of blocking cholesterol uptake into the enterocyte at the brush border membrane, they also demonstrate that once ezetimibe treatment ceases, there is a rapid return toward normal levels of cholesterol absorption (Fig. 3A) and the pathways that govern cholesterol homeostasis in the enterocyte (Fig. 3B) .
The fourth conclusion concerns the relative expression of NPC1L1 mRNA in the liver and extrahepatic organs of the Golden Syrian hamster compared to what has been reported for other animal models (1, 36) and humans (1, 12) . Although such comparative data remain limited, and are based on mRNA rather than protein or activity measurements, it appears that in humans there is a much greater relative expression of mRNA for NPC1L1 in liver compared to other tissues than is the case in the few animal species where this has been investigated. Based on the present data, the Golden Syrian hamster appears to be more like the rat, mouse, and miniature pig in that the dominant site of expression of NPC1L1 message is the small bowel, with comparatively little being present in the liver (Fig 2, (1, 36) ). In the hamster, NPC1L1 mRNA was detected in the gallbladder at levels higher than those seen in the liver, but still trivial (Fig. 5-7 ) make two points that bear directly on this question. One is that by placing a major block on absorption at the level of cholesterol uptake by the enterocyte, the dramatic and adverse changes in intrahepatic cholesterol metabolism and biliary cholesterol content associated with consumption of the high cholesterol, high fat diet are greatly attenuated (Fig. 5-7) . The other is that although there was a detectable increase in the cholesterol concentration in the bile when hamsters fed the REGULATION OF BILIARY CHOLESTEROL SECRETION IN HAMSTERS 20 low cholesterol basal diet were given ezetimibe, the corresponding increase associated with feeding the lipid rich diet alone was far greater (Fig 7A) . More importantly however, was the finding that ezetimibe treatment, given concurrently with this diet, resulted in a reduction in the absolute (Fig. 7A) and relative (Fig.7D) cholesterol content of the bile to values at or near those seen in matching hamsters given the basal diet alone. Herein lies the potential relevance of these data in the hamster to the question of long term ezetimibe treatment and biliary cholesterol levels in humans. Based on our current understanding of all the factors that can impact the level of biliary cholesterol saturation, it seems that any increase in biliary cholesterol levels that might arise from an effect of ezetimibe directly on the activity of NPC1L1 on the canalicular surface of hepatocytes would be more than offset by the marked reduction in the inflow of chylomicron cholesterol to the liver and the potential that this has to drive up biliary cholesterol content.
Added to this is the point that ezetimibe is most widely used as an add-on to statins which are known to reduce biliary cholesterol content (38). That aside, the present data, together with the results of a recent study demonstrating a favorable effect of short-term ezetimibe treatment on biliary cholesterol levels in humans (51), suggest that a clinical trial designed to investigate the potential of ezetimibe for reducing biliary cholesterol saturation in populations with a predisposition to cholelithiasis is now warranted. The relative mRNA level for HMG CoA synthase in the same tissues was determined in separate matching groups of hamsters (H). Here, each value was expressed relative to the mRNA level in the colon of hamsters not given ezetimibe, which was arbitrarily set at 1.0. All values are means ± SE of data from 5 to 7 animals in each group. *Significantly different from corresponding value for matching group not given ezetimibe, P < 0.05. proteins in the small intestine of female Golden Syrian hamsters after withdrawal of ezetimibe treatment. As described in Materials and Methods, female hamsters were given one of three treatments over a 10-day period. One group received only the basal diet, while a second group was fed the same diet containing ezetimibe (2 mg/day per kg bw). A third group received the diet with ezetimibe for 10 days, but was started on this diet 3 days ahead of the other group. These hamsters were switched back to the basal diet alone 3 days before they, and the other two groups, were dosed intragastrically with labeled sterols for the measurement of fractional cholesterol absorption (A). For all three groups, stools were collected for 3 days after dosing. The hamsters were then terminated and the small intestine was removed for the measurement of the relative expression level of mRNA for various proteins (B). Values are means ± SE of data from 4 animals (no treatment) and 7 animals in each of the ezetimibe and ezetimibe (withdrawn) groups.
*Significantly different from corresponding value for group not given ezetimibe, P < 0.05. or with ezetimibe (right). Hepatic and plasma cholesterol levels (B and C, respectively) were measured as described in Materials and Methods. Values are means ± SE of data from 6 or 7 animals in each group. *Significantly different from corresponding value for group fed basal diet without ezetimibe, P < 0.05. ‡Significantly different from value for group fed lipid-rich diet without ezetimibe, P < 0.05. without or with ezetimibe. Gallbladder bile was harvested from male Golden Syrian hamsters that were fed the same diets as were used in the study described in the legend for Fig. 6 , and biliary lipid concentrations were measured as described in Materials and Methods. Values are means ± SE of data from 7 or 8 animals in each group. *Significantly different from corresponding value for group fed basal diet without ezetimibe, P < 0.05. ‡ Significantly different from corresponding value for group fed lipid-rich diet without ezetimibe, P <0 .05. 
